ACXP Acurx Pharmaceuticals, Inc.: Rasio total nilai perusahaan marang pendapatan

Simbol resmi perusahaan Acurx (ACXP)

Acurx Pharmaceuticals focuses on bringing advanced antibiotics to market to combat resistant gastrointestinal infections. The company's enterprise value-to-revenue trend clearly confirms the valuation dynamics, with the latest mark standing at 0.00. Stable demand for such drugs makes the business non-cyclical, while future success depends entirely on FDA approval and Fast Track status.

ACXP Multiplikator EV/Sales Acurx Pharmaceuticals, Inc. (23.11.2025 - 20.11.2026)

ACXP (Acurx Pharmaceuticals, Inc.): rincian analitis lan laporan miturut indikator

- data kapitalisasi saham perusahaan:
Pambiji fundamental:Acurx Pharmaceuticals, ACXP
Produk seri acurxpharma.com

This metric determines the fundamental value of the business by combining market capitalization and net debt per unit of revenue to identify the actual overvaluation of the asset. By analyzing the EV/Sales ratio, an investor assesses the capitalization efficiency of Acurx Pharmaceuticals (ACXP) developments in the antibiotics sector, where the absence of large-scale industrial facilities and compliance with environmental standards minimize off-balance sheet risks affecting the company's valuation.